Dry-Eye Phase III Trial Enrolled, OphthaliX 'Wets' Oral Appetite

Osborne, Randy
March 2013
BioWorld Today;3/19/2013, Vol. 24 Issue 52, p1
The article reports that OphthaliX has tackled its first-in-class A3 adenosine receptor agonist CF101 in a 24-week, 236-patient placebo-controlled Phase III trial. It states that serendipity data provided by patients in a rheumatoid arthritis (RA) trial with CF101 led to dry-eye syndrome (DES) experiments. Pnina Fishman, chief executive officer (CEO) of Can-Fite BioPharma Ltd., said they saw the data and decided to proceed with the trial. Symptoms of DES are mentioned.


Related Articles

  • Can-Fite's CF101 delivers can-do performance in RA. Powers, Marie // BioWorld Today;12/24/2013, Vol. 24 Issue 246, p1 

    The article reports that Can-Fite Biopharma Ltd. impressed investors with results from its Phase IIb trial results of CF101 drug product as a monotherapy for rheumatoid arthritis (RA). It says that the study demonstrated statistically significant quality compared to placebo in reducing RA signs...

  • CLINIC ROUNDUP.  // BioWorld Today;7/15/2009, Vol. 20 Issue 134, p6 

    This section offers news briefs related to several clinical trials. A Phase I/II trial with CF102 for the treatment of hepatitis C virus by Can-Fite BioPharma of Petach Tikva, Israel will begin to enroll patients. Enrollment for the first of two ongoing blinded, placebo-controlled, multicenter,...

  • CAN-FITE BIOPHARMA INITIATES CF102 TRIAL FOR LIVER CANCER.  // Worldwide Biotech;May2009, Vol. 21 Issue 5, p8 

    This article reports on the plan of Can-Fite BioPharma of Israel to conduct a I/II clinical trial with CF102 for the treatment of liver cancer in 2009. Can-Fite announced that it will start enrolling patients for the clinical trial. The company will investigate the safety and efficacy of CF102...

  • CLINIC ROUNDUP.  // BioWorld Today;5/6/2008, Vol. 19 Issue 88, p4 

    This section offers news briefs on the pharmaceutical industry. Anesiva Inc. has announced the publication of data from a Phase III trial of Zingo powder intradermal injection in "Journal Pediatrics." Can-Fite BioPharma has successfully completed a Phase I trial with its second pipeline drug,...

  • CLINIC ROUNDUP.  // BioWorld Today;4/2/2010, Vol. 21 Issue 63, p7 

    This section offers news briefs on clinical trials including the completion by Can-Fite BioPharma Ltd. of patient recruitment for its Phase 1/II trial of CF102 in the treatment of patients with advanced hepatocellular carcinoma and the initiation by Symphogen A/S of a Phase I/II trial in the U.S.

  • CLINIC ROUNDUP.  // BioWorld Today;5/25/2010, Vol. 21 Issue 100, p7 

    This section offers news briefs on clinical trials in the biopharmaceutical industry as of May 25, 2010. The Israeli Ministry of Health has given its approval for the Phase II trial of orally administered CF101 in glaucoma by Can-Fite BioPharma Ltd. The Swedish Medical Products Agency has...

  • CLINIC ROUNDUP.  // BioWorld Today;4/17/2009, Vol. 20 Issue 73, p5 

    This section offers news briefs on clinical trials within the biotechnology industry. The Israel Ministry of Health and Rabin MC Ethics Committee have approved the Phase I/II trial of Can-Fite BioPharma for CF102 for the treatment of liver cancer. Diamyd Medical AB plans to cut costs by...

  • CLINIC ROUNDUP.  // BioWorld Today;5/1/2009, Vol. 20 Issue 83, p8 

    This section offers news briefs on clinical trials. Results from Can-Fite BioPharma's Phase IIb study in rheumatoid arthritis patients indicate that the study failed to achieve its primary efficacy endpoint. XOMA Ltd. has completed patient enrollment in its Phase I study of XOMA 052 which...

  • CLINIC ROUNDUP.  // BioWorld Today;6/5/2007, Vol. 18 Issue 108, p3 

    The article offers news briefs on issues related to medicine trials. Acorda Therapeutics Inc. has presented a meta-analysis of data on 501 multiple sclerosis patients from two clinical trials of Fampridine-SR. Bionovo Inc. has released mixed results from its double-blind, placebo-controlled,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics